Upcoming Dialogues

Winter/Spring Series 2021


Heart Health: Prevention, Lifestyle and Wellness
Thursday, January 21, 2021

2 p.m. EST / 1 p.m. CST / Noon MST / 11 a.m. PST


By combining traditional Western medicine with a holistic approach to overall wellness and disease prevention, Dr. Andrew Freeman helps patients achieve exceptional results. He will discuss blending advanced cardiology diagnostics and lifestyle medicine to include a whole food, plant-based diet; regular exercise; mindfulness; and ongoing support for improved health. Dr. Freeman has been nicknamed "The Vegan Cardiologist", for combining lifestyle changes with the latest evidence-based medications.

His clinical interests and expertise are in general cardiology, preventive cardiology, heart failure and cardiomyopathy, diastolic dysfunction (abnormal relaxation of the heart), chest pain and shortness of breath, and heart problems caused by respiratory problems and high blood pressure (hypertension), as well as nutrition and lifestyle medicine.


Andrew M. Freeman, MD, FACC, FACP
Director of Cardiovascular Prevention and Wellness
Director, Clinical Cardiology & Operations
Associate Professor, Department of Medicine


Register Now  

 

Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF)
Thursday, February 18, 2021

2 p.m. EST / 1 p.m. CST / Noon MST / 11 a.m. PST

Hear about the latest developments in research and treatment of interstitial lung diseases (ILD). Particularly emphasis will be on idiopathic pulmonary fibrosis (IPF), one of more than 130 types of ILD, which is characterized by scarring and/or inflammation of the interstitium - the area surrounding the air sacs at the end of each airway in the lungs.

Both the Pulmonary Fibrosis Foundation and the National Institutes of Health have recognized National Jewish Health for its expertise in IPF and ILD. Our cutting-edge research and exceptional quality of care offers our patients access to the latest clinical trials and most effective treatments.

Dr. Swigris is regarded as the world’s leading expert on quality of life issues in patients with ILD. His individual research interests include understanding how patients live with and experience ILD, how we assess that experience, and how caretakers might improve quality of life in patients suffering from ILD.

Dr. Elizabeth Redente is studying, among other things, how fibroblasts (cells that make scar tissue) are shaping the lung environment during disease and how targeting these cells to die can be modulated to influence disease resolution in fibrosis and more.


Elizabeth F. Redente, PhD
Researcher, Division of Cell Biology
Associate Professor, Department of Pediatrics


Jeffrey James Swigris, DO, MS
Director, Interstitial Lung Disease Program
Professor, Department of Medicine


Register Now  

 

Exercise Intolerance: Breathing Trouble When Exercising
Thursday, March 18, 2021

2 p.m. EDT / 1 p.m. CDT / Noon MDT / 11 a.m. PDT

The National Jewish Health Exercise & Performance Breathing Center in Denver, Colorado is the premiere center for evaluating and treating barriers to exercise related to the lungs and heart. We care for athletes at every level - from children, to Olympians, to adults looking to exercise for enjoyment and health.

Patients travel across the country for diagnosis and treatment of exercise-induced asthma, a myriad other heart and lung conditions that present themselves during physical exertion, and exercise-induced laryngeal obstruction, also known as vocal cord dysfunction, for which Dr. Tod Olin pioneered treatment.


J. Tod Olin, MD, MSCS 
Director, Exercise and Performance Breathing Center
Associate Professor, Department of Pediatrics
Associate Professor, Department of Medicine


Register Now  

 

The Intersection of Autoimmune Diseases and the Lung: Rheumatoid Arthritis, Systematic Sclerosis (Scleroderma) and Myositis
Thursday, April 15, 2021

2 p.m. EDT / 1 p.m. CDT / Noon MDT / 11 a.m. PDT

Autoimmune diseases cause the immune system to attack both harmful and healthy cells in the body. This attack of healthy cells can occur in the joints, and nearly every organ in the body. When systemic autoimmune diseases, including rheumatoid arthritis, inflammatory myositis, systemic sclerosis scleroderma, and Sjogren's syndrome affect the lungs, they can cause lung disease.

This program will share how autoimmune diseases impact the lungs and how National Jewish Health physicians and scientists are leading in research and treatment of these diseases. Our rheumatologists work collaboratively with the Interstitial Lung Disease and Pulmonary programs to provide unparalleled care for patients.

Dr. Maleki Fischbach studies the genetic and clinical manifestations of Sjogren’s syndrome and is currently conducting clinical trials for systemic sclerosis (scleroderma).

Dr. Solomon is interested in the cause, outcomes and treatment of interstitial lung diseases and specifically on those related to autoimmune diseases.


Mehrnaz Maleki Fischbach, MD
Director, Rheumatology Clinic & Scleroderma Program
Associate Professor, Department of Medicine


Joshua J. Solomon, MD
Associate Chief, Section of Critical Care
Autoimmune Lung Center and Interstitial Lung Disease Program
Associate Professor, Department of Medicine


Register Now  

 

Making Strides in the Treatment of Cystic Fibrosis
Thursday, May 13, 2021

2 p.m. EDT / 1 p.m. CDT / Noon MDT / 11 a.m. PDT

National Jewish Health runs the largest adult cystic fibrosis (CF) program in the country. CF is a genetic and progressive disease that affects the lungs and digestive system. CF worsens over time as a result of persistent lung infections and damage that make it difficult to breathe. Fortunately, steady advances in medical treatments for CF have provided a range of therapies to slow or prevent complications. 

Hear from Drs. Jennifer Taylor-Cousar and Pamela Zeitlin about the latest advances in research and treatment of adult and pediatric CF, including a study led by researchers at National Jewish Health that demonstrates how a three-drug combination can improve lung function, reduce exacerbations and improve quality of life. This discovery is one that could ultimately help 90% of people with CF.


Jennifer L. Taylor-Cousar, MD, MSCS, ATSF
Medical Director, Clinical Research Services
Co-Director, Adult Cystic Fibrosis Program
Director, Cystic Fibrosis Therapeutics Development Center Adult Program
Professor, Department of Medicine and Department of Pediatrics


Pamela L. Zeitlin, MD, MPhil, PhD
Silverstein Chair, Department of Pediatrics
Professor, Department of Pediatrics


Register Now  

 

Big Impact Ideas: Our Next Life-Changing Discoveries
Thursday, June 17, 2021

2 p.m. EDT / 1 p.m. CDT / Noon MDT / 11 a.m. PDT

Recent advances in medicine and technology have helped accelerate the path to life-changing discoveries with immense potential impact. Hear from Dr. Greg Downey about the advances at National Jewish Health that will lead to: 

  • Curing Severe Asthma 
  • Stopping the Progression of COPD
  • Preventing Childhood Allergies
  • Repairing and Restoring Function to the Damaged Lung

Dr. Downey’s areas of interest include; basic immunology, cellular and molecular biology, infectious diseases and inflammation. He currently serves as an associate editor of American Journal of Respiratory Cell and Molecular Biology.


Gregory P. Downey, MD 
Executive Vice President, Academic Affairs and Provost
Drs. Harold and Mary Zirin Chair, Adult Pulmonary Biology
Professor, Department of Medicine


Register Now  

 

Have questions for the docs? Click below to submit a question.


Submit Questions  

Do you have family or friends that might be interested? Share the njhealth.org/docseries link.